secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001628280-24-003781
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024
--------------------------------------------------------------------------------

- Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.
- Lilly plans to file an IND for FHD-909 in Q2 2024 for BRG1 mutated NSCLC.
- FHD-909 targets BRG1 mutant non-small cell lung cancer, exploiting BRM dependency.
- Collaboration with Lilly announced Dec 2021 includes US 50/50 co-development and co-commercialization.
- Foghorn and Lilly plan to present preclinical data at upcoming scientific conferences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024003781/0001628280-24-003781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024003781/fhtx-20240208.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-003781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer